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The authors of this review of managing difficult to treat asthma state that studies of novel 
biologic agents have shown marked improvements in exacerbation frequency, health care 
consumption, and reductions in oral steroid dosage, but that there is limited evidence to 
demonstrate benefits in quality of life. Failure to detect quality of life improvement amongst 
so many other improvements may be the fault of the quality of life instruments, not the drug. 
Current asthma quality of life scales were designed for patients with mild to moderate asthma 
but have not been designed to assess the burden of disease and treatment in the most severe 
asthmatics1. In severe asthma oral corticosteroids impose a high level of adverse effects as 
perceived by patients. These adverse effects can be ameliorated by reductions in oral 
corticosteroids that can be achieved when patients start biologic a treatment. NICE has 
confirmed that important factors related to oral steroid burden had not been captured when 
calculating the quality of life adjusted life years (QALY).2 The newly developed Severe 
Asthma Questionnaire (www.saq.org.uk ) was developed specifically using the input of 
patients with severe asthma to meet current Food and Drug Administration standards on 
HRQoL questionnaire design.3 The SAQ is currently undergoing validation but represents a 
more content and construct valid HRQoL outcome measure for patients with severe asthma. 
Only if appropriate measures are used to assess the specific health deficits experienced by 
people with severe asthma can interventions that improve HRQoL be evaluated accurately. 
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